FDA Approves Veppanu for Some Forms of Advanced Breast Cancer

Originally published by our sister publication Specialty Pharmacy ContinuumBy PPN StaffThe FDA approved vepdegestrant (Veppanu, Arvinas Operations) for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced, or metastatic breast cancer who have experienced disease progression following at least one line of endocrine therapy.The agency also approved the Guardant360 CDx—a comprehensive genomic profiling panel—as a companion diagnostic device to identify patie